文献速递神经肌肉病

神经丝轻链:无症状肌萎缩侧索硬化及临床转化的候选生物标志物

Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion.
PubMed 文献 · Ann Neurol · 2018-08-16

研究纳入84例ALS高危个体、34例对照、17例ALS患者和10例临床转化者,采用电化学发光免疫分析检测血清和脑脊液NfL。结果显示ALS患者NfL显著高于对照和高危个体且相对稳定,临床转化者在症状出现前约12个月NfL已升高。血清和脑脊液NfL是无症状ALS的信息性生物标志物,可能有助于早期干预和预防试验设计。

要点

  • ALS患者血清和脑脊液NfL显著高于对照和高危个体,且随时间相对稳定。
  • 临床转化者在最早临床症状或体征出现前约12个月NfL已高于对照范围。
  • 血清和脑脊液NfL是无症状ALS的信息性生物标志物,可能预测临床转化时间。

核心结论

  • 血清和脑脊液NfL是无症状ALS的信息性生物标志物,为量化无症状疾病进展和潜在预测临床转化时间提供了新工具。
  • NfL定量可能有助于为受影响个体设计实施早期治疗干预和/或为短期风险个体设计疾病预防试验。

研究设计与样本

  • 研究人群包括84例有ALS风险的个体、34例对照、17例ALS患者和10例临床转化者(在临床显性疾病出现前后均观察的高危个体)。
  • 高危个体通过无症状家族性ALS(Pre-fALS)研究入组,该研究是对携带任何ALS相关基因突变(SOD1、C9orf72、TARDBP、FUS、VCP等)但入组时无显性疾病临床症状或体征(包括肌电图证据)个体的纵向自然史和生物标志物研究。
  • 血清和脑脊液NfL采用电化学发光免疫分析定量。

主要发现

  • ALS患者血清和脑脊液NfL显著高于对照和高危个体,且随时间相对稳定。
  • 临床转化者中,NfL水平在最早临床症状或体征出现前约12个月即已升高(即高于对照观察范围)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS). METHODS: The study population includes 84 individuals at risk for developing ALS, 34 controls, 17 ALS patients, and 10 phenoconverters (at-risk individuals observed both before and after the emergence of clinically manifest disease). At-risk individuals are enrolled through Pre-Symptomatic Familial ALS (Pre-fALS), a longitudinal natural history and biomarker study of individuals who are carriers of any ALS-associated gene mutation (in SOD1, C9orf72, TARDBP, FUS, VCP, etc), but who, at the time of enrollment, demonstrated no clinical symptoms or signs (including electromyographic evidence) of manifest disease. NfL in serum and cerebrospinal fluid (CSF) were quantified using an electrochemiluminescence immunoassay. RESULTS: Serum and CSF NfL are substantially higher in ALS patients compared to controls and at-risk individuals and remain relatively stable over time. Among phenoconverters, however, NfL levels were elevated (ie, above the range observed in controls) as far back as ∼12 months preceding the emergence of the earliest clinical symptoms or signs of disease. INTERPRETATION: Serum (and CSF) NfL are informative biomarkers of presymptomatic ALS, providing a new tool to quantify presymptomatic disease progression and to potentially predict the timing of clinical phenoconversion. As such, quantification of NfL may aid the design and implementation of early therapeutic intervention for affected individuals and/or disease prevention trials for individuals at short-term risk of developing ALS. Ann Neurol 2018 Ann Neurol 2018;83:130-139.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Benatar M, Wuu J, Andersen PM, et al. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018. PMID: 30014505. doi:10.1002/ana.25276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。